EP3356522A4 - Zusammensetzungen mit proteinbeladenem exosom und verfahren zur herstellung und freisetzung davon - Google Patents

Zusammensetzungen mit proteinbeladenem exosom und verfahren zur herstellung und freisetzung davon Download PDF

Info

Publication number: EP3356522A4
Authority: EP; European Patent Office
Prior art keywords: delivering; preparing; methods; same; compositions containing
Prior art date: 2016-09-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP17856859.8A

Other languages

English (en)

French (fr)

Other versions

EP3356522A1 (de

Inventor

Chulhee Choi

Kyungsun CHOI

Seung-Wook RYU

Nambin YIM

Hojun CHOI

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Ilias Biologics Inc

Original Assignee

Cellex Life Sciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-09-30

Filing date

2017-09-29

Publication date

2019-03-27

2016-09-30 Priority claimed from KR1020160126961A external-priority patent/KR101912315B1/ko

2016-09-30 Priority claimed from KR1020160126335A external-priority patent/KR101877010B1/ko

2016-09-30 Priority claimed from KR1020160126921A external-priority patent/KR101912313B1/ko

2016-10-04 Priority claimed from KR1020160127486A external-priority patent/KR101912310B1/ko

2016-10-13 Priority claimed from KR1020160132616A external-priority patent/KR101900465B1/ko

2017-09-29 Application filed by Cellex Life Sciences Inc filed Critical Cellex Life Sciences Inc

2018-08-08 Publication of EP3356522A1 publication Critical patent/EP3356522A1/de

2019-03-27 Publication of EP3356522A4 publication Critical patent/EP3356522A4/de

Status Withdrawn legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
- C12Y111/01—Peroxidases (1.11.1)
- C12Y111/01015—Peroxiredoxin (1.11.1.15)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Medicinal Chemistry (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Microbiology (AREA)
Immunology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Marine Sciences & Fisheries (AREA)
Hematology (AREA)
Toxicology (AREA)
Diabetes (AREA)
Mycology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Oncology (AREA)

EP17856859.8A 2016-09-30 2017-09-29 Zusammensetzungen mit proteinbeladenem exosom und verfahren zur herstellung und freisetzung davon Withdrawn EP3356522A4 (de)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
KR1020160126961A KR101912315B1 (ko)	2016-09-30	2016-09-30	Bax 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 유효성분으로 함유하는 암 예방 및 치료용 약학적 조성물
KR1020160126335A KR101877010B1 (ko)	2016-09-30	2016-09-30	super-repressor-IκB 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 유효성분으로 함유하는 염증성 질환 예방 및 치료용 약학적 조성물
KR1020160126921A KR101912313B1 (ko)	2016-09-30	2016-09-30	Cre 재조합 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 유효성분으로 함유하는 표적 유전자의 조건적 녹아웃 대립유전자를 생성하기 위한 조성물
KR1020160127486A KR101912310B1 (ko)	2016-10-04	2016-10-04	페록시레독신 i 또는 ii 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 유효성분으로 함유하는 항산화용 약학적 조성물
KR1020160132616A KR101900465B1 (ko)	2016-10-13	2016-10-13	CRISPR-CAS family를 이용한 게놈 에디팅 툴을 엑소솜으로 전달하는 기술
KR20170018637		2017-02-10
PCT/KR2017/011070 WO2018062973A1 (en)	2016-09-30	2017-09-29	Compositions containing protein loaded exosome and methods for preparing and delivering the same

Publications (2)

Publication Number	Publication Date
EP3356522A1 EP3356522A1 (de)	2018-08-08
EP3356522A4 true EP3356522A4 (de)	2019-03-27

Family

ID=61760013

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP17856859.8A Withdrawn EP3356522A4 (de)	2016-09-30	2017-09-29	Zusammensetzungen mit proteinbeladenem exosom und verfahren zur herstellung und freisetzung davon

Country Status (7)

Country	Link
EP (1)	EP3356522A4 (de)
JP (1)	JP2019528674A (de)
CN (1)	CN108473973A (de)
AU (1)	AU2017335084B2 (de)
CA (1)	CA3002520A1 (de)
IL (1)	IL259023B (de)
WO (1)	WO2018062973A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20180177727A1 (en) *	2015-06-10	2018-06-28	Board Of Regents, The University Of Texas System	Use of exosomes for the treatment of disease
US10709797B2 (en)	2017-08-16	2020-07-14	City University Of Hong Kong	Isolation of extracellular vesicles (EVs) from red blood cells for gene therapy
IL277447B2 (en) *	2018-04-10	2024-04-01	Brainstorm Cell Therapeutics Ltd	Cell-adapted exosomes and their uses
CN110387416B (zh) *	2018-04-16	2022-06-17	华东理工大学	可控聚合调控功能的纳米金双探针体系及其应用
AU2019312212B2 (en) *	2018-07-24	2024-10-10	Mayo Foundation For Medical Education And Research	Compositions and methods involving transforming extracellular vesicles
CN110885789A (zh) *	2018-09-05	2020-03-17	中国科学院生物物理研究所	高效可控包装內源核酸的工程化外泌体制备及其应用
CN109097336A (zh) *	2018-09-07	2018-12-28	深圳市新仑生物科技有限公司	一种干细胞外泌体、制备方法及应用
US20210355492A1 (en) *	2018-09-21	2021-11-18	City University Of Hong Kong	Cargo loaded extracellular vesicles
US11766484B2 (en)	2019-01-03	2023-09-26	International Business Machines Corporation	Exosome vessels for delivery of molecular cargo
KR102125567B1 (ko) *	2019-07-02	2020-06-22	한양대학교 에리카산학협력단	식물 엑소좀의 대량 생산 방법
CN110669723A (zh) *	2019-11-08	2020-01-10	赵凯	一种基于差速离心法的细胞外泌体提取工艺
AU2020419182A1 (en) *	2019-12-30	2022-08-25	Ilias Therapeutics, Inc.	Compositions containing exosome carrying NF-KB inhibitors and methods of using thereof
US11970718B2 (en)	2020-01-13	2024-04-30	Carmine Therapeutics Pte. Ltd.	Nucleic acid loaded extracellular vesicles
KR102688170B1 (ko)	2020-02-10	2024-07-24	주식회사 엑소스템텍	광 절단성 단백질을 포함하는 엑소좀 및 이의 이용
JP7479078B2 (ja)	2020-02-10	2024-05-08	株式会社エキソステムテック	光切断性タンパク質を含むエクソソーム及びその用途
CN113388584A (zh) *	2020-03-10	2021-09-14	路宝特（南京）环保科技有限公司	一种促进皮肤组织损伤后修复用工程化外泌体的制备方法及其应用
CN115335079A (zh) *	2020-03-31	2022-11-11	伊利亚斯生物制品公司	基于外泌体递送nf-kb抑制剂的用途
CN111905105B (zh) *	2020-07-02	2023-05-05	华南师范大学	一种用于癌症靶向治疗的蛋白类纳米药物及其制备方法
CN114716548B (zh)	2021-01-05	2024-11-05	(株)爱恩德生物	抗-fgfr3抗体及其用途
CN113234686A (zh) *	2021-04-28	2021-08-10	大连干细胞与精准医学创新研究院	一种靶蛋白递送载体的制备方法
CN114878833A (zh) *	2021-07-01	2022-08-09	浙江大学	一种检测抗过氧化物还原酶-1-IgG抗体的试剂盒
CN116355858A (zh) *	2023-05-29	2023-06-30	北京大学	一种用于递送CRISPR-Cas9的工程化细胞外囊泡及其制备方法和用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0018901D0 (en) *	2000-08-03	2000-09-20	Biovation Ltd	Peptides presented by cells
EP1417229B1 (de) *	2001-08-17	2011-06-15	Exothera L.L.C.	Verfahren und zusammensetzung zum gezielten einbringen in exosome
KR100519384B1 (ko)	2002-08-13	2005-10-06	(주)누백스	유전자 이입을 이용한 엑소좀의 제조방법 및 상기 엑소좀의 용도
EP2613149B1 (de)	2007-07-25	2014-09-17	University Of Louisville Research Foundation, Inc.	Exosomassoziierte microRNA als Diagnosemarker
SG190670A1 (en)	2008-02-01	2013-06-28	Gen Hospital Corp	Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions
US8431530B2 (en) *	2009-06-12	2013-04-30	Morehouse School Of Medicine	Compositions and methods for treating aids or cancer by inhibiting the secretion of microparticles
RU2012103482A (ru) *	2009-07-02	2013-08-10	АйТиЭйч ИММЬЮН ТЕРАПИ ХОЛДИНГЗ АБ	Способ лечения рака, основанный на использовании экзосом
FR2950350B1 (fr) *	2009-09-24	2013-12-13	Centre Nat Rech Scient	Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations
SG183579A1 (en) *	2011-02-11	2012-09-27	Agency Science Tech & Res	Methods of detecting therapeutic exosomes
US9708381B2 (en) *	2011-09-30	2017-07-18	Korea Advanced Institute Of Science And Technology	Method for forming a reversible protein nanocluster using light in a cell
WO2013089738A1 (en) *	2011-12-15	2013-06-20	Morehouse School Of Medicine	Compositions and methods for exosome targeted expression
KR101433057B1 (ko) *	2012-03-07	2014-09-23	한국과학기술원	빛에 의해 ｒｔｋ 신호전달을 활성화하는 융합단백질 및 그의 용도
WO2014168548A2 (en) *	2013-04-12	2014-10-16	El Andaloussi, Samir	Therapeutic delivery vesicles
US20160186208A1 (en) *	2013-04-16	2016-06-30	Whitehead Institute For Biomedical Research	Methods of Mutating, Modifying or Modulating Nucleic Acid in a Cell or Nonhuman Mammal
CN103468642A (zh) *	2013-09-23	2013-12-25	山西大学	一种分离细胞培养基中外泌体的方法
JP6773563B2 (ja) *	2014-05-18	2020-10-21	ザチルドレンズメディカルセンターコーポレーション	エキソソームに関連する方法および組成物
WO2016044947A1 (en) *	2014-09-26	2016-03-31	Exerkine Corporation	Exosomes useful to treat lysosomal storage disease
CA2965530A1 (en) *	2014-11-07	2016-05-12	Wisconsin Alumni Research Foundation	Targeting dna vaccines to b cells
WO2016143805A1 (ja) *	2015-03-10	2016-09-15	テオリアサイエンス株式会社	膀胱がんの検出方法
KR20160130937A (ko) *	2015-05-04	2016-11-15	한국과학기술원	목적 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 이용하여 목적 단백질을 세포질로 전달시키는 방법

2017
- 2017-09-29 EP EP17856859.8A patent/EP3356522A4/de not_active Withdrawn
- 2017-09-29 WO PCT/KR2017/011070 patent/WO2018062973A1/en active Application Filing
- 2017-09-29 IL IL259023A patent/IL259023B/en unknown
- 2017-09-29 JP JP2018530580A patent/JP2019528674A/ja active Pending
- 2017-09-29 CA CA3002520A patent/CA3002520A1/en active Pending
- 2017-09-29 AU AU2017335084A patent/AU2017335084B2/en active Active
- 2017-09-29 CN CN201780003826.5A patent/CN108473973A/zh active Pending

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HANEY MATTHEW J ET AL: "Exosomes as drug delivery vehicles for Parkinson's disease therapy", JOURNAL OF CONTROLLED RELEASE, vol. 207, 31 March 2015 (2015-03-31), pages 18 - 30, XP029226653, ISSN: 0168-3659, DOI: 10.1016/J.JCONREL.2015.03.033 *
NAMBIM YIM: "Supplementary Information files for: Exosome engineering for efficient intracellular delivery of soluble proteins using optically reversible protein-protein interaction module.", NAT. COMMUN., 22 July 2016 (2016-07-22), XP055552398, Retrieved from the Internet <URL:https://media.nature.com/original/nature-assets/ncomms/2016/160721/ncomms12277/extref/ncomms12277-s1.pdf> [retrieved on 20190206] *
NAMBIN YIM ET AL: "Exosome engineering for efficient intracellular delivery of soluble proteins using optically reversible protein-protein interaction module", NATURE COMMUNICATIONS, NATURE PUBLISHING GROUP, GB, vol. 7, 22 July 2016 (2016-07-22), pages 1 - 9, XP002779472, ISSN: 2041-1723, Retrieved from the Internet <URL:http://www.nature.com/articles/ncomms12277.pdf> DOI: 10.1038/NCOMMS12277 *

Also Published As

Publication number	Publication date
IL259023B (en)	2022-09-01
JP2019528674A (ja)	2019-10-17
WO2018062973A1 (en)	2018-04-05
CN108473973A (zh)	2018-08-31
IL259023A (en)	2018-07-31
CA3002520A1 (en)	2018-04-05
EP3356522A1 (de)	2018-08-08
AU2017335084A1 (en)	2018-05-10
AU2017335084B2 (en)	2023-06-29

Publication	Publication Date	Title
EP3356522A4 (de)	2019-03-27	Zusammensetzungen mit proteinbeladenem exosom und verfahren zur herstellung und freisetzung davon
IL267033A (en)	2019-07-31	Preparations and methods for administering nucleic acid and/or protein cargo
HK1247854A1 (zh)	2018-10-05	混合變應原組合物及其使用方法
EP3355954A4 (de)	2020-01-08	Freisetzungsverfahren und zusammensetzungen
EP3285594A4 (de)	2018-12-05	Freisetzungssysteme und verfahren zur herstellung davon
EP3474857A4 (de)	2020-03-18	Zusammensetzungen und verfahren zur abgabe von therapiemitteln
EP3512554A4 (de)	2020-06-17	Plättchenzusammensetzungen und verfahren zur ausgabe von therapeutischen agenten
EP3668552A4 (de)	2021-04-28	Exosomen zur zielspezifischen verabreichung und verfahren zu ihrer herstellung und verabreichung
EP3305802A4 (de)	2019-01-09	Neuartiges peptid und zusammensetzung damit
EP3548616A4 (de)	2020-05-13	Tau-modulatoren und verfahren und zusammensetzungen zur abgabe davon
EP3457869A4 (de)	2019-05-22	Lager- und liefersystem
EP3331947A4 (de)	2019-04-17	Kieselsäurebasierter biomolekülträger, pharmazeutische zusammensetzung damit, herstellungsverfahren und verwendung davon
EP3426304A4 (de)	2019-11-27	Nanolipoproteinpartikel und zugehörige zusammensetzungen sowie systeme zur verbesserten wirkstoffbeladung
IL265831A (en)	2019-06-30	Preparations and methods for protein expression and administration
EP3515417A4 (de)	2020-08-05	Ausgabevorrichtungen und verfahren zur herstellung davon
IL268997B1 (en)	2023-05-01	Preparations containing pgi2 receptor agonists and processes for their preparation
EP3479835A4 (de)	2020-03-25	Zusammensetzung zur verwendung bei der verbesserung des ernährungszustandes
EP3466269A4 (de)	2020-02-19	Zusammensetzung mit koffein und cycloalanylalanin
EP3468570A4 (de)	2020-01-01	Zusammensetzungen für biologische systeme und verfahren zur herstellung und verwendung davon
EP3512529A4 (de)	2020-05-06	Arzneimittelverabreichungszusammensetzungen und -verfahren
EP3341327A4 (de)	2019-04-24	Partikelförmige hydroxyapatitzusammensetzungen und verfahren zur herstellung davon
EP3319930A4 (de)	2019-04-10	Verfahren und zusammensetzungen zur stabilisierung von proteinen
EP3615005A4 (de)	2021-03-10	Zusammensetzungen und verfahren zur verabreichung von impfungen
EP3328434A4 (de)	2019-03-13	Pharmazeutische zusammensetzung mit verbesserter lagerstabilität und verfahren zur herstellung davon
EP3328435A4 (de)	2019-03-13	Pharmazeutische zusammensetzung mit verbesserter lagerstabilität und verfahren zur herstellung davon

Legal Events

Date	Code	Title	Description
2018-04-07	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2018-07-06	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2018-07-06	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2018-08-08	17P	Request for examination filed	Effective date: 20180430
2018-08-08	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2018-08-08	AX	Request for extension of the european patent	Extension state: BA ME
2019-03-27	A4	Supplementary search report drawn up and despatched	Effective date: 20190221
2019-03-27	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 38/47 20060101ALI20190215BHEP Ipc: A61K 9/127 20060101ALI20190215BHEP Ipc: C12N 15/113 20100101ALI20190215BHEP Ipc: C12N 15/63 20060101ALI20190215BHEP Ipc: C12N 9/24 20060101AFI20190215BHEP Ipc: C12N 15/88 20060101ALI20190215BHEP Ipc: C12N 9/22 20060101ALI20190215BHEP Ipc: C12N 15/85 20060101ALI20190215BHEP
2020-01-08	DAV	Request for validation of the european patent (deleted)
2020-01-08	DAX	Request for extension of the european patent (deleted)
2020-04-01	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: ILIAS BIOLOGICS INC.
2020-04-21	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2020-05-27	17Q	First examination report despatched	Effective date: 20200424
2021-01-26	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2021-11-19	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2024-05-03	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2024-06-05	18D	Application deemed to be withdrawn	Effective date: 20240118